Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels?

L. Del Pup, F. A. Peccatori

Research output: Contribution to journalArticle

Abstract

Very high progesterone levels (mean 186.6 ± 43.6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH. Results highlight the need to further evaluate this in larger series. While waiting, the clinical significance of high progesterone levels can be drawn from epidemiological and experimental data here reviewed in order to give reassurance to the clinician involved in fertility preservation. If the progesterone increase will be confirmed, epidemiological and experimental data do not seem to indicate a detrimental effect or they could even be protective. As this possible rise of levels is a very short event in the very long lasting and multifactorial breast carcinogenesis, it is unlikely that it will significantly influence breast cancer prognosis.

Original languageEnglish
Pages (from-to)246-249
Number of pages4
JournalEuropean Review for Medical and Pharmacological Sciences
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

letrozole
Ovulation Induction
Progesterone
Breast Neoplasms
Fertility Preservation
Luteal Phase
Carcinogenesis
Breast

Keywords

  • Breast cancer
  • Fertility protection
  • Infertility
  • Letrozole
  • Ovulation induction
  • Progesterone

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{52211521212841e9816b717c08382892,
title = "Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels?",
abstract = "Very high progesterone levels (mean 186.6 ± 43.6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH. Results highlight the need to further evaluate this in larger series. While waiting, the clinical significance of high progesterone levels can be drawn from epidemiological and experimental data here reviewed in order to give reassurance to the clinician involved in fertility preservation. If the progesterone increase will be confirmed, epidemiological and experimental data do not seem to indicate a detrimental effect or they could even be protective. As this possible rise of levels is a very short event in the very long lasting and multifactorial breast carcinogenesis, it is unlikely that it will significantly influence breast cancer prognosis.",
keywords = "Breast cancer, Fertility protection, Infertility, Letrozole, Ovulation induction, Progesterone",
author = "{Del Pup}, L. and Peccatori, {F. A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.26355/eurrev-201801-14125",
language = "English",
volume = "22",
pages = "246--249",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "1",

}

TY - JOUR

T1 - Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels?

AU - Del Pup, L.

AU - Peccatori, F. A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Very high progesterone levels (mean 186.6 ± 43.6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH. Results highlight the need to further evaluate this in larger series. While waiting, the clinical significance of high progesterone levels can be drawn from epidemiological and experimental data here reviewed in order to give reassurance to the clinician involved in fertility preservation. If the progesterone increase will be confirmed, epidemiological and experimental data do not seem to indicate a detrimental effect or they could even be protective. As this possible rise of levels is a very short event in the very long lasting and multifactorial breast carcinogenesis, it is unlikely that it will significantly influence breast cancer prognosis.

AB - Very high progesterone levels (mean 186.6 ± 43.6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH. Results highlight the need to further evaluate this in larger series. While waiting, the clinical significance of high progesterone levels can be drawn from epidemiological and experimental data here reviewed in order to give reassurance to the clinician involved in fertility preservation. If the progesterone increase will be confirmed, epidemiological and experimental data do not seem to indicate a detrimental effect or they could even be protective. As this possible rise of levels is a very short event in the very long lasting and multifactorial breast carcinogenesis, it is unlikely that it will significantly influence breast cancer prognosis.

KW - Breast cancer

KW - Fertility protection

KW - Infertility

KW - Letrozole

KW - Ovulation induction

KW - Progesterone

UR - http://www.scopus.com/inward/record.url?scp=85040778323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040778323&partnerID=8YFLogxK

U2 - 10.26355/eurrev-201801-14125

DO - 10.26355/eurrev-201801-14125

M3 - Article

VL - 22

SP - 246

EP - 249

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 1

ER -